Elicera Therapeutics AB (8E8) Financial Statements
Elicera Therapeutics AB Financial Overview
Elicera Therapeutics AB's market cap is currently $16.09M. The company's EPS TTM is $-0.35; its P/E ratio is -7.51; Elicera Therapeutics AB is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 7.13M | $ 11.23M | $ 1.28M | $ 587.00 |
| Gross Profit | $ 0.00 | $ 7.13M | $ 11.22M | $ 1.28M | $ -11.19K |
| Operating Income | $ -17.94M | $ -16.88M | $ -28.33M | $ -19.36M | $ -13.12M |
| EBITDA | $ -17.40M | $ -16.87M | $ -17.08M | $ -19.43M | $ -13.11M |
| Net Income | $ -17.41M | $ -16.11M | $ -16.40M | $ -19.52M | $ -13.12M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 24.85M | $ 26.40M | $ 29.38M | $ 43.82M | $ 52.39M |
| Total Assets | $ 27.42M | $ 27.56M | $ 30.18M | $ 46.31M | $ 54.74M |
| Total Debt | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Net Debt | $ -24.85M | $ -26.40M | $ -29.38M | $ -43.82M | $ -52.39M |
| Total Liabilities | $ 4.06M | $ 6.79M | $ 13.78M | $ 13.51M | $ 2.50M |
| Stockholders' Equity | $ 23.36M | $ 20.77M | $ 16.40M | $ 32.80M | $ 52.24M |
| Cash Flow | |||||
| Free Cash Flow | $ -21.55M | $ -23.46M | $ -14.92M | $ -8.57M | $ -14.29M |
| Operating Cash Flow | $ -21.55M | $ -23.46M | $ -14.92M | $ -8.57M | $ -14.29M |
| Investing Cash Flow | $ 1.00K | $ 0.00 | $ 483.17K | $ 0.00 | $ -1.00K |
| Financing Cash Flow | $ 20.00M | $ 20.48M | $ 0.00 | $ 0.00 | $ 55.12M |
Currency in SEK